| Bronchial asthma is the most common chronic respiratory disease in children, whose incidence has been increasing with the development of society. Asthma has become a grave public health problem drawing worldwide attention for it severely causes a huge burden to families and society. In Clinical, Chinese medicine treatment of chronic asthma has unique advantages. The prescription Gubenfangxiao decoction (GBFXD) is an empirical prescription from Professor Jiang Yuren who is a countrywide famous pediatrician. It provided the effects of nourishing lung, secured exterior, invigorated spleen and resolved phlegm. GBFXD is an effective prescription to cure childhood asthenia of pulmonosplenic qi. GBFXD is clinical safety. Currently in the national science pillar program, named as "The effects of Gubenfangxiaoyin on the susceptibility gene (ADAM33and ORMDL3) of asthma and related regulatory、signal transduction", has reached the experimental stage. The experimental research part of our work belongs to this project, and part investigates further mechanism of GBFXD as well as its active components preventing and curing asthma using views of both Cytokines and Lung tissue pathology.ObjectExplore the mechanism of GBFXD and Astragalus polysaccharides preventing and curing asthma remission period using views of observing the levels of IL-4and IL-5in BALF of mouse.MethodsBALB/c mice were sensitized with intraperitoneal OVA injection and atomization inhalation, then sensitized mice involved with several periods of atomization inhaled OVA challenges。The model mice which stopped inspire were divided into four groups, namely the model group, montelukast sodium group, GBFXD group and astragalus polysaccharide group. The mice were administered28days. The IL-4and IL-5levels in BALF and lung histological examinations were observed24hours after last administration.ResultsLung lesion score result of46-day model mice was significantly higher than the normal group (p<0.05), lung lesion score result of90-day model mice was significantly higher than he normal group (p<0.05), lung lesion scores results of46-day model mouse was slightly above the90-day model group (p>0.05).Lungs of normal mice showed no inflammatory cell infiltration, bronchial wall integrity, no congestion and edema of the mucosa; Lungs of model mice showed wall thickening, and inflammatory cell infiltration, epithelial cell degeneration of the branching airway wall. Lung pathological changes were significantly improved, the lungs bronchial wall hyperplasia were reduced, and airway remodelings were improved after giving GBFXD.Compared to the model group, The IL-4levels in BALF had no significant effect of GBFXD. Compared to the normal group, The IL-4levels in BALF did not change significantly in remission asthma period of BALB/c mice. montelukast sodium group, GBFXD group, astragalus polysaccharide group were not statistically significant compared with the model group.The IL-5level in the mouse model BALF had higher than normal group (P<0.05); The IL-5level in montelukast group had slightly lower than the model group, but not statistically significant (P>0.05); The IL-5level in the GBFXD group decreased significantly than the model group (P<0.05); The IL-5level in astragalus polysaccharide group had slightly higher than the montelukast group, and slightly lower than the model group, but not statistically significant (P>0.05).ConclusionThe lung lesions of46days model mice and90days model mice were not statistically significant. Considering reasons of the time and economic, the model program select46days model mice.The GBFXD and the montelukast can improve lung pathology progress of mouse in asthma remission.The GBFXD in the treatment of asthma in remission may be reduced the level of IL-5in BALF. |
PDF Full Text Request